ArticleVox sanguinis2025
Nucleic acid testing in Colombian blood banks (2018-2024): Implementation, yield estimates and implications for safer transfusion policy.
Article in Vox sanguinis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current perspectives and updates on transfusion strategies in critically ill anemic patients.Frontiers in medicine · 2026Review
- Nucleic acid testing in Colombian blood banks (2018-2024): Implementation, yield estimates and implications for safer transfusion policy.Vox sanguinis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
BACKGROUND AND
objectivesColombia has a population of 52.6 million inhabitants and a blood donation rate of 26 donations per 1000 inhabitants. The 84 blood banks in the country collect approximately 1 million donations annually, which are mandatorily screened for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human T-lymphotropic virus (HTLV), Trypanosoma cruzi and Treponema pallidum. Currently, 95% of donations are screened using chemiluminescence and the remaining using enzyme-linked immunosorbent assays (ELISA). However, nucleic acid testing (NAT) is not mandatory for any infectious agent. The aim was to assess the progress in the voluntary implementation of NAT for HIV, HBV and HCV in blood banks. MATERIALS AND
methodsData from the National Haemovigilance Information System were analysed between January 2018 and December 2024, including the total number of donations collected and the screening results obtained through chemiluminescence, ELISA as well as NAT in blood banks that voluntarily adopted this technology.
resultsDuring the study period, a total of 6,435,189 blood units were collected, of which 6.9% were screened using NAT. The data revealed 10 undetected immunological windows with conventional techniques: four for HIV, three for HBV and three for HCV. It is estimated that the universal implementation of NAT would have identified 135 additional infectious units, potentially preventing at least 83 infections in recipients.
conclusionThe progressive implementation of NAT in Colombian blood banks has demonstrated the presence of immunological windows undetectable by conventional serological techniques, highlighting the potential risk for blood recipients. These findings underscore the need to accelerate NAT adoption and consider making it mandatory in 100% of the country's blood banks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.